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In the July issue of Nature Medicine, Massague´ and colleagues define a biphasic role for the extracellular
matrix protein tenascin C as ametastatic niche component in lung colonization by breast cancer cells. These
results provide a rationale for designing therapies targeting metastatic progression by disrupting its very
foundations.While dissemination can occur early
during tumor progression (Hu¨semann
et al., 2008; Podsypanina et al., 2008),
the ability to colonize distant sites may
not be so ‘‘easily’’ achieved. The dy-
namics of metastatic growth vary widely
among patients, perhaps reflecting the
extent to which the primary tumor is able
to cultivate a supportive niche at the
distant site prior to dissemination (i.e., a
premetastatic niche) or how pre-adapted
disseminated tumor cells (DTCs) are to
‘‘foreign soil.’’
The contribution of bone marrow-
derived cells in establishing the pre-
metastatic niche is well described, and ef-
fectors (e.g., fibronectin, lysyl oxidase,
MMP-9, S100A8/A9, and TNF-a) that
prime amicroenvironment for DTC growth
continue to be uncovered (Kaplan et al.,
2005; Psaila and Lyden, 2009) (Figure 1).
The tumor cells’ ability to elicit distant ex-
pression of such factors influences organ
tropism (Kaplan et al., 2005), and the
presence of extracellular matrix (ECM)
proteins and ECM-remodeling enzymes
at the premetastatic site reflects the re-
quirement for signaling through specific
adhesion receptors to support engraft-
ment and survival of incoming metastatic
cells (Psaila and Lyden, 2009). But how
this extracellular milieu changes during
progression from a premetastatic to
metastatic microenvironment remains ill
defined. Moreover, little is known about
the properties of the first DTCs that colo-
nize and build the foundations of the
metastatic niche, or the mechanisms by
which they conquer ‘‘foreign soil.’’
A recent Nature Medicine paper pro-
vides a functional characterization of anorgan-specific driver of metastasis, the
ECM glycoprotein tenascin-C (TNC)
(Oskarsson et al., 2011).
In this study, Massague´ and colleagues
build upon their earlier work (Minn et al.,
2005) to elegantly define a novel role for
TNC in initiating and sustaining lung colo-
nization by breast tumor cells (Oskarsson
et al., 2011). The authors show that while
TNC knockdown does not hinder mam-
mary tumor growth, it restricts the pro-
gression of lung micrometastases. The
presence of TNC at the borders of meta-
static lesions suggests it may provide
a supportive scaffold that fosters progres-
sion of lung metastases. This conclusion
is reinforced by the array of biochemical
interactions supported by TNC’s molec-
ular structure.
TNC is a complex hexabranchion con-
taining EGF- and fibronectin-like repeats
and a C-terminal fibrinogen-like globular
domain, which mediate its interaction
with ECM proteins and cell-surface mole-
cules. TNC may signal directly or within
macromolecular scaffolds, suggesting
that TNC binding triggers signaling in a
context-dependent fashion determined
by whether it is coupled to other ECM
molecule(s), the identity of said molecules
(e.g., fibronectin or fibrinogen), and the
size of the signaling complex formed
(which could theoretically affect integrin
clustering and signal strength) (Hynes,
2009). These factors may underlie cancer
cell type- and organ-specific responses
to TNC, and thus dictate the efficacy of
therapeutically targeting TNC in a given
setting. These properties also form the
basis for TNC’s pleiotropic effects during
development, inflammation, and tumori-Cancer Cell 20genesis. Since TNC is dramatically down-
regulated in adult tissues, its reinduction
in tumors and the surrounding microenvi-
ronment may reflect the acquisition of a
migratory or stem cell-like phenotype by
tumor cells (Ben-Porath et al., 2008).
To address the significance of TNC in
breast tumor colonization of the lung,
Oskarsson et al. (2011) knockdown TNC
after tumor cells engraft the lung. In so
doing, they demonstrate that the dynamic
and reciprocal interplay between a cell
and its microenvironment that generally
drives tissue specificity (Bissell et al.,
1982) also forms the foundation for sig-
naling between ‘‘seed’’ and ‘‘soil’’ within
a metastatic niche. While ablation of
TNC expression in DTCs early during the
metastatic process inhibits the outgrowth
of lung metastases, late inhibition does
not affect progression from micro- to
macrometastases. By this later time point,
metastatic cells have already induced
lung stroma activation, which coincides
with increased expression of TNC by
lung cells. The simplest interpretation of
these results is that stromal TNC obviates
the need for tumor-derived TNC, a hypo-
thesis that could be rigorously explored
via tissue-specific knockdown. Moreover,
determining whether preexisting TNC
expression by nontumor cells in the lung
can compensate for lack of DTC-derived
TNC upon arrival and identifying the
cellular source of TNC in the reactive
lung would provide further insight into
TNC’s role in the metastatic niche, as
would elucidating the mechanism that
drives paracrine TNC signaling during
metastatic progression. Addressing such
issues is crucial to determining whether, August 16, 2011 ª2011 Elsevier Inc. 139
Figure 1. Biphasic Roles of Tenascin C in Breast Cancer Metastasis
TNC may promote tumor cell dissemination and survival during the early steps of metastasis by concentrating growth factors (e.g., EGF, FGF) or through recip-
rocal interactions with ECM components such as fibronectin, heparan-sulfate proteoglycans (e.g syndecan 4, versican, perlecan, aggrecan) and fibrinogen,
enzymes such as matrix metalloproteinases, and cell surface receptors such as EGFR and integrins. During progression from micro- to macrometastasis, acti-
vation of surrounding lung tissue elicits expression of TNC in the host organ (green matrix), in addition to that derived from the tumor cells (blue matrix). While the
cellular source of host TNC and the specific effects of tumor- and host cell-derived TNCon various cell typeswithin themetastatic milieu remain to be determined,
it is likely that at least some of the niche-derived TNC is of endothelial origin. TNC may be a key component of the metastatic niche within organs other than the
lung, including bone marrow. The organ specificity of TNC-mediated interactions between breast cancer cells (as well as other cancer types) and other host
organs remains to be elucidated.
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presents a valid target for therapiesmeant
to prevent micrometastases from thriving
in the lung. Further clues may be gleaned
by examining the kinetics of lung metas-
tases in cancer patients with chronic ob-
structive pulmonary disorder, a disease
characterized by TNC overexpression in
the lung epithelium.
Oskarsson et al. (2011) further explore
the mechanisms through which TNC
confers lung-colonizing capacity upon
breast tumor cells. Although silencing
TNC in breast tumor oncospheres does
not affect the expression of putative stem
cell markers, Wnt and Notch signaling
are downregulated, and restoration of140 Cancer Cell 20, August 16, 2011 ª2011 ENotch signaling is sufficient to circumvent
the need for TNC in lung colonization.
Thus, TNC evidently enhances the fitness
of breast cancer cells in the lung, but not
their self-renewal capacities, in a Notch
and Wnt-signaling dependent manner.
One obvious question arises from these
data: how does TNC regulate Notch and
Wntsignaling in tumorcells?TNCmayacti-
vateWnt signaling indirectly by binding the
transmembraneproteoglycanSyndecan4,
known to activate noncanonical Wnt
signaling (Mun˜oz et al., 2006). In contrast,
the presence of EGF-like repeats in TNC
opens up the intriguing possibility that
TNC may activate Notch signaling dir-
ectly by acting as a non-canonical Notchlsevier Inc.ligand; biochemical and functional binding
assays are necessary to test this hypoth-
esis. Given that Notch signaling is required
not only for normal mammary gland and
breast cancer development but also for
angiogenesis and vascular remodeling, it
will be crucial to determine whether the
altered balance of TNC in the metastatic
niche engages Notch and Wnt signaling
in the tumor-associated endothelium,
activating a feed-forward loop that pro-
motes angiogenesis and secretion of cyto-
kines/chemokines, further supporting
tumor growth.
An intriguing yet underexplored func-
tion of TNC is its potential involvement in
the establishment and/or maintenance of
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forebrain development. It is conceivable
that TNC contributes to the generation of
a stem-cell like niche supporting cancer-
initiating cell survival and proliferation at
newly colonized metastatic sites. Never-
theless, it remains to be determined
whether TNC plays a role in normal mam-
mary stem cell niches, and whether TNC
is required for breast cancer initiating
cell survival, proliferation, and homing
in vivo.
Identifying factors involved in facilitating
the early and late stages of metastasis
may provide targeted therapies that effec-
tively hinder disease progression. TNC
may represent one such target that can
be attacked to unravel the metastatic
niche of the lung (and perhaps other
tissues) at its foundation. Whether target-
ing stromal-derived TNC in addition to
DTC-derived TNC will prove sufficient tocause regression of established metas-
tases remains an open question. But as
a major determinant of metastatic in-
itiation and sustenance of both tumor
and microenvironmental provenance,
TNCmay indeed represent one of the first
opportunities to develop two-pronged
therapies that simultaneously target a
‘‘seed-’’ and ‘‘soil-intrinsic’’ prometastatic
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